Article
Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.
Radiation oncology (London, England) - 12 Sept 2011
Davies Janine M, Trembath Dimitri, Deal Allison M, Funkhouser William K, Calvo Benjamin F, Finnegan Timothy, Weck Karen E, Tepper Joel E, O'Neil Bert H
Abstract excerpt
BACKGROUND: KRAS mutations may predict poor response to radiotherapy. Downstream events from KRAS, such as activation of BRAF, AKT and ERK, may also confer prognostic information but have not been tested in rectal cancer (RC). Our objective was to explore the relationships of KRAS and BRAF mutation status with p-AKT and p-ERK and outcomes in RC. METHODS: Pre-radiotherapy RC tumor biopsies were evaluated. KRAS and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.